Skip to main content
SpringerLink
Log in

Wirksamkeit und Sicherheit des Kombinations-Nasensprays Olopatadinhydrochlorid-Mometasonfuroat in der Behandlung der allergischen Rhinitis

  • Kongressabstracts
  • Published:
Allergo Journal Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Klimek F, Bergmann C, Hagemann J, Cuevas M, Klimek L. Therapieoptionen bei der saisonalen (intermittierenden) allergischen Rhinitis. Allergologie 2023;46:590-602

  2. Compalati E, Canonica GW. Efficacy and safety of rupatadine for allergic rhino-conjunctivitis: a systematic review of randomized, double-blind, placebo-controlled studies with meta-analysis. Curr Med Res Opin 2013;29:1539-51

  3. Lynde CW, Sussman G, Dion P-L, Guenther L, Hébert J, Rao J et al. Multidisciplinary Real-World Experience With Bilastine, a Second Generation Antihistamine. J Drugs Dermatol 2020;19:145-54

  4. U.S. Food and Drug Administration: Ryaltris (olopatadine hydrochloride and mometasone furoate monohydrate nasal spray) 2022 www.accessdata.fda.gov/drugsatfda_docs/label/2022/211746s000lbl.pdf; [letzter Aufruf: 7.9.2023]

  5. Lim L, Lipari M, Kale-Pradhan P. Intranasal Olopatadine-Mometasone in the Treatment of Seasonal Allergic Rhinitis. Ann Pharmacother 2023;57:570-8

  6. Fairchild CJ, Meltzer EO, Roland PS, Wells D, Drake M, Wall GM. Comprehensive report of the efficacy, safety, quality of life, and work impact of Olopatadine 0.6 % and Olopatadine 0.4 % treatment in patients with seasonal allergic rhinitis. Allergy Asthma Proc 2007;28:716-23

  7. Hochhaus G. Pharmacokinetic/pharmacodynamic profile of mometasone furoate nasal spray: potential effects on clinical safety and efficacy. Clin Ther 2008;30:1-13

  8. Meltzer EO, Hampel FC, Ratner PH, Bernstein DI, Larsen LV, Berger WE et al. Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2005;95:600-6

  9. Penagos M, Eifan AO, Durham SR, Scadding GW. Duration of Allergen Immunotherapy for Long-Term Efficacy in Allergic Rhinoconjunctivitis. Curr Treat Options Allergy 2018;5:275-90

  10. Simons FER, Simons KJ. Histamine and H1-antihistamines: celebrating a century of progress. J Allergy Clin Immunol 2011;128:1139-50.e4

  11. Berlucchi M, Pedruzzi B. Intranasal mometasone furoate for treatment of allergic rhinitis. Clinical Medicine Insights: Therapeutics 2010;2:761-9

  12. Lipiec A, Jurkiewicz D. A new therapeutic option in the management of allergic rhinitis. Otolaryngol Pol 2021;75:1-5

  13. Patel P, Salapatek AM, Talluri RS, Tantry SK. Pharmacokinetics of intranasal mometasone in the fixed-dose combination GSP301 versus two monotherapy intranasal mometasone formulations. Allergy Asthma Proc 2018; 39:232-9

  14. Patel P, Salapatek AM, Talluri RS, Tantry SK. Pharmacokinetics of intranasal olopatadine in the fixed-dose combination GSP301 versus two monotherapy intranasal olopatadine formulations. Allergy Asthma Proc 2018;39:224-31

  15. Alcon Laboratories I. Patanase (olopatadine hydrochloride) Nasal Spray 2009; www.accessdata.fda.gov/drugsatfda_docs/label/2009/021861s002lbl.pdf [letzter Aufruf: 7.9.2023]

  16. Andrews CP, Mohar D, Salhi Y, Tantry SK. Efficacy and safety of twice-daily and once-daily olopatadine-mometasone combination nasal spray for seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2019;124:171-8.e2

  17. Patel P, Salapatek AM, Tantry SK. Effect of olopatadine-mometasone combination nasal spray on seasonal allergic rhinitis symptoms in an environmental exposure chamber study. Ann Allergy Asthma Immunol 2018;122:160-6.e1

  18. Gross GN, Berman G, Amar NJ, Caracta CF, Tantry SK. Efficacy and safety of olopatadine-mometasone combination nasal spray for the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2019;122:630-8.e3

  19. Hampel FC, Pedinoff AJ, Jacobs RL, Caracta CF, Tantry SK. Olopatadine-mometasone combination nasal spray: Evaluation of efficacy and safety in patients with seasonal allergic rhinitis. Allergy Asthma Proc 2019;40:261-72

  20. Segall N, Prenner B, Lumry W, Caracta CF, Tantry SK. Long-term safety and efficacy of olopatadine-mometasone combination nasal spray in patients with perennial allergic rhinitis. Allergy Asthma Proc 2019;40:301-10

  21. Dykewicz MS, Wallace DV, Amrol DJ, Baroody FM, Bernstein JA, Craig TJ et al. Rhinitis 2020: A practice parameter update. J Allergy Clin Immunol 2020;146:721-67

  22. Nickels AS, Dimov V, Wolf R. Pharmacokinetic evaluation of olopatadine for the treatment of allergic rhinitis and conjunctivitis. Expert Opin Drug Metab Toxicol 2011;7:1593-9

  23. Penagos M, Compalati E, Tarantini F, Baena-Cagnani CE, Passalacqua G, Canonica GW. Efficacy of mometasone furoate nasal spray in the treatment of allergic rhinitis. Meta-analysis of randomized, double-blind, placebo-controlled, clinical trials. Allergy 2008;63:1280-91

  24. Seidman MD, Gurgel RK, Lin SY, Schwartz SR, Baroody FM, Bonner JR et al. Clinical practice guideline: allergic rhinitis executive summary. Otolaryngol Head Neck Surg 2015;152:197-206

  25. Bielory L, Chun Y, Bielory BP, Canonica GW. Impact of mometasone furoate nasal spray on individual ocular symptoms of allergic rhinitis: a meta-analysis. Allergy 2011;66:686-93

  26. Herman H. Once-daily administration of intranasal corticosteroids for allergic rhinitis: a comparative review of efficacy, safety, patient preference, and cost. Am J Rhinol 2007;21:70-9

  27. Fifer S, Toh L, Barkate H, Aggarwal V, Borade D, Gordonsmith RH et al. Patient Satisfaction and Sensory Attributes of Nasal Spray Treatments of Olopatadine Hydrochloride/Mometasone Furoate Monohydrate and Azelastine Hydrochloride/Fluticasone Propionate for Allergic Rhinitis in Australia - An Observational Real-World Clinical Study. Patient Prefer Adherence 2023;17:141-51

  28. Chen R, Zheng D, Zhang Y, Sima G. Efficacy and safety of twice-daily olopatadine-mometasone combination nasal spray (GSP301) in the treatment of allergic rhinitis: a systematic review and meta-analysis. Eur Arch Otorhinolaryngol 2022;279:1691-9

  29. Gebrauchsinformation: Information für Patienten - Dymista Nasenspray 137 μg/50 μg pro Sprühstoß - Nasenspray, Suspension; Azelastinhydrochlorid/Fluticasonpropionat: Viatris Healthcare GmbH; 2022; https://go.sn.pub/dymista/beipackzettel [letzter Aufruf: 7.11.2023].

  30. Klimek L, Bachert C, Pfaar O, Becker S, Bieber T, Brehler R et al. ARIA guideline 2019: treatment of allergic rhinitis in the German health system. Allergologie select 2019;3:22-50

  31. Klimek L, Casper I, Bergmann KC. Therapy of allergic rhinitis in routine care: evidence-based benefit assessment of freely combined use of various active ingredients. A position paper of the Medical Association of German Allergists (AEDA) in cooperation with the ENT section of the European Academy of Allergy and Clinical Immunology (EAACI),the German ARIA (Allergic Rhinitis and its Impact on Asthma) Group and the Working Group Clinical Immunology, Allergology and Environmental Medicine of the German Society for Otorhinolaryngology, Head and Neck Surgery (DGHNO-KHC). Allergo J Int 2020;29,129-38

  32. Kim M, Ryu G, Kang SY, Kim MA, Yang SI, Lee IH et al. Intranasal antihistamine and corticosteroid to treat allergic rhinitis: A systematic review and meta-analysis. Allergy 2022;77:3436-40

  33. Klimek L, Klimek F, Bergmann C, Hagemann J, Cuevas M, Becker S. Efficacy and safety of the combination nasal spray olopatadine hydrochloride-mometasone furoate in the treatment of allergic rhinitis. Allergo J Int 2024;33:9-19

Download references

Author information

Authors and Affiliations

  1. FA für HNO-Heilkunde u. Allergologie, Zentrum f. Rhinologie und Allergologie, An den Quellen 10, 65183, Wiesbaden, Deutschland

    Ludger Klimek

  2. Zentrum für Rhinologie und Allergologie Wiesbaden, An den Quellen 10, 65183, Wiesbaden, Deutschland

    Felix Klimek

  3. HNO im RKM740 interdisziplinäre Facharztklinik, Pariser Straße 83-89, 40549, Düsseldorf, Deutschland

    Christoph Bergmann

  4. Klinik f. Hals-Nasen-Ohrenheilkunde, Universitätsmedizin Mainz, Langenbeckstraße 1, 55131, Mainz, Deutschland

    Jan Hagemann

  5. Klinik u. Poliklinik für Hals- Nasen- und Ohrenheilkunde, Univ.-Klinikum Carl Gustav Carus, Fetscherstr. 74, 01307, Dresden, Deutschland

    Mandy Cuevas

  6. Universitätsklinik für Hals-, Nasen-, und Ohrenheilkunde, Universitätsklinik Tübingen, Elfriede-Aulhorn-Straße 5, 72076, Tübingen, Deutschland

    Sven Becker (Leitender Oberarzt / Stellvertretender Ärztlicher Direktor)

Authors
  1. Ludger Klimek
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Felix Klimek
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christoph Bergmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jan Hagemann
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mandy Cuevas
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sven Becker
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Klimek, L., Klimek, F., Bergmann, C. et al. Wirksamkeit und Sicherheit des Kombinations-Nasensprays Olopatadinhydrochlorid-Mometasonfuroat in der Behandlung der allergischen Rhinitis. Allergo J 33, 45–49 (2024). https://doi.org/10.1007/s15007-024-6263-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15007-024-6263-8

Search

Navigation